# Glycitin

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/glycitin
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-05
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** 4'-hydroxy-6-methoxyisoflavone-7-O-glucoside, 6-methoxy-4'-hydroxyisoflavone-7-glucoside, Glycitin glucoside, 7-O-glucosyl-6-methoxyisoflavone, Soy isoflavone glycoside, 6-methoxygenistin derivative

## Overview

Glycitin is a naturally occurring isoflavone glycoside found predominantly in soybeans and soy-derived foods, structurally characterized by a 7-O-glucoside linkage on the glycitein aglycone. It exerts its primary biological effects through estrogen receptor modulation (ERα and ERβ) and suppression of pro-[inflammatory](/ingredients/condition/inflammation) signaling cascades including NF-κB and TNF-α pathways.

## Health Benefits

• [Anti-inflammatory](/ingredients/condition/inflammation) effects demonstrated in preclinical models, reducing TNF-α-induced cytokines and preserving extracellular matrix in nucleus pulposus cells (preliminary evidence)
• Potential anticancer properties shown in vitro through G0/G1 cell cycle arrest and apoptosis induction in gastric, breast, and glioblastoma cells (preliminary evidence)
• [Antioxidant activity](/ingredients/condition/antioxidant) via ROS scavenging and Nrf2-ARE pathway activation, though only demonstrated in laboratory studies (preliminary evidence)
• May support intervertebral disc health by inhibiting inflammatory mediators and preserving collagen II/aggrecan in animal models (preliminary evidence)
• No genotoxicity observed in human clinical trial at 300-600mg/day equivalents, suggesting safety profile (limited clinical evidence)

## Mechanism of Action

Glycitin binds selectively to estrogen receptors ERα and ERβ as a phytoestrogen, modulating downstream gene transcription involved in cell proliferation and inflammation. It inhibits the NF-κB signaling pathway, thereby reducing transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α, IL-1β, and IL-6, while also preserving extracellular matrix integrity in nucleus pulposus cells by downregulating MMP-3 and MMP-13 expression. Additionally, glycitin induces apoptosis in cancer cell lines via caspase-3 activation and promotes G0/G1 cell cycle arrest by modulating cyclin D1 and CDK4 expression.

## Clinical Summary

The majority of evidence supporting glycitin's bioactivity comes from in vitro cell culture studies and rodent preclinical models, with limited direct human clinical trials isolating glycitin as a single agent. In vitro studies have demonstrated G0/G1 cell cycle arrest and apoptosis induction in gastric and breast cancer cell lines at concentrations ranging from 10–100 μM. [Anti-inflammatory](/ingredients/condition/inflammation) effects, including suppression of TNF-α-induced cytokine release and extracellular matrix degradation in nucleus pulposus cells, have been documented in preclinical models, though translation to human outcomes remains unconfirmed. Most human data on isoflavones derives from mixed-isoflavone interventions (daidzein, genistein, glycitin combined), making it difficult to attribute specific effects to glycitin alone.

## Nutritional Profile

Glycitin is a pure isoflavone glycoside compound (molecular formula C22H24O10, molecular weight 462.42 g/mol), not a whole food, so traditional macronutrient/micronutrient profiling does not apply. As a bioactive compound, its profile is characterized as follows: It is a methoxylated isoflavone consisting of a glycitein aglycone (7-hydroxy-6-methoxyisoflavone) conjugated to a glucose moiety at the 7-position via a beta-glycosidic bond. Glycitin is one of the three primary soy isoflavone glycosides, typically found in soy-based foods alongside daidzin and genistin. In soy products, glycitin/glycitein compounds represent the smallest fraction of total isoflavones, comprising approximately 5–10% of total soy isoflavone content (compared to ~50% daidzin and ~40% genistin). Concentrations in whole soybeans range approximately 0.1–0.5 mg/g dry weight; in soy protein isolates approximately 0.05–0.2 mg/g; in fermented soy products (miso, tempeh) glycitin is partially hydrolyzed to its aglycone glycitein, which may reach 0.1–0.3 mg/g. Bioavailability: As a glycoside, glycitin requires intestinal beta-glucosidase or microbial hydrolysis to release the active aglycone glycitein before absorption. Absorption occurs primarily in the small intestine post-hydrolysis; bioavailability is estimated at 20–40% relative to aglycone forms, with significant inter-individual variation depending on [gut microbiome](/ingredients/condition/gut-health) composition. The methoxy group at position 6 distinguishes glycitein/glycitin from other soy isoflavones and may confer slightly different receptor-binding and metabolic properties. No caloric, fiber, protein, vitamin, or mineral contribution is applicable as this is an isolated phytochemical compound.

## Dosage & Preparation

No standardized human dosages established for isolated glycitin. In the single clinical trial, soy isoflavone mixtures containing glycitein were dosed at 300-600mg genistein equivalents/day. Soy isoflavone supplements typically provide 20-120mg total isoflavones/day, with glycitin comprising 10-20% in soy germ extracts. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Glycitin is generally considered safe when consumed through dietary soy sources, though isolated high-dose supplementation lacks robust long-term human safety data. Due to its phytoestrogenic activity at ERα and ERβ, individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer, uterine fibroids, or endometriosis should consult a physician before supplementing. Glycitin may interact with tamoxifen and other selective estrogen receptor modulators (SERMs) by competing for receptor binding, potentially altering therapeutic efficacy. Pregnant and breastfeeding women should exercise caution, as high-dose isoflavone exposure during sensitive developmental windows has shown effects on reproductive hormone signaling in animal models.

## Scientific Research

Human clinical evidence for glycitin is extremely limited, with only one Phase I trial (n=20 men with prostate cancer plus 6 controls) testing soy isoflavone mixtures containing glycitein aglycone at 300-600mg genistein equivalents/day for up to 84 days, showing no genotoxicity (PMID: 12663286). No dedicated RCTs or meta-analyses exist for glycitin alone, with most data derived from preclinical in vitro and animal models.

## Historical & Cultural Context

While glycitin as an isolated compound is not documented in traditional medicine, it is inherent to soybeans used in Traditional Chinese Medicine for over 2,000 years to tonify qi, clear heat, and treat [cardiovascular](/ingredients/condition/heart-health) and [inflammatory](/ingredients/condition/inflammation) conditions. Fermented soy products rich in isoflavones have been traditionally consumed in Japanese Kampo for [bone health](/ingredients/condition/bone-health) and menopausal symptoms.

## Synergistic Combinations

Genistein, Daidzein, Quercetin, Resveratrol, Curcumin

## Frequently Asked Questions

### What is the difference between glycitin, glycitein, and daidzein?

Glycitin is the 7-O-glucoside conjugate of glycitein, meaning it is glycitein with a glucose molecule attached, which affects its bioavailability and intestinal absorption. Glycitein is the aglycone (sugar-free) form and is the active compound after enzymatic cleavage by intestinal beta-glucosidases. Daidzein is a structurally related but distinct soy isoflavone lacking the 6-methoxy group that characterizes the glycitein/glycitin family.

### What foods are highest in glycitin?

Glycitin is found almost exclusively in soybeans and soy-derived products, where it typically represents the smallest fraction of the three major soy isoflavones alongside daidzin and genistin. Fermented soy products such as miso, tempeh, and natto tend to have higher proportions of the aglycone form (glycitein) because fermentation activates beta-glucosidase enzymes that cleave the glucose moiety. Raw or minimally processed soybeans and soy flour contain the highest total isoflavone concentrations, with glycitin content typically ranging from 5–20 mg per 100g depending on variety and processing.

### Can glycitin help with inflammation?

Preclinical evidence suggests glycitin can reduce inflammation by inhibiting the NF-κB signaling pathway and lowering levels of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in cell and animal models. One notable study demonstrated glycitin preserved nucleus pulposus cell extracellular matrix integrity under TNF-α-induced inflammatory stress, with reductions in MMP-3 and MMP-13 expression. However, no controlled human clinical trials have directly tested glycitin supplementation for inflammatory conditions, so these findings remain preliminary.

### Does glycitin have anticancer properties?

In vitro studies have shown glycitin can induce G0/G1 cell cycle arrest and trigger apoptosis via caspase-3 activation in gastric and breast cancer cell lines at concentrations of approximately 10–100 μM. It modulates cyclin D1 and CDK4 expression, disrupting cancer cell proliferation cycles. These findings are currently limited to laboratory models, and no human clinical trials have evaluated glycitin as a standalone anticancer agent, so it should not be considered a cancer treatment.

### Is glycitin safe for people with thyroid conditions?

Soy isoflavones including glycitin have been shown in some studies to inhibit thyroid peroxidase (TPO), an enzyme critical for thyroid hormone synthesis, which raises concern for individuals with hypothyroidism or those taking levothyroxine. At typical dietary soy intake levels, this interaction is generally considered clinically insignificant for people with healthy thyroid function and adequate iodine status. However, individuals on thyroid hormone replacement therapy should separate soy isoflavone supplementation from their medication by at least four hours to minimize potential absorption interference, and consult an endocrinologist before using concentrated isoflavone supplements.

### What is the current quality of clinical evidence for glycitin's health benefits?

Most evidence for glycitin comes from preclinical laboratory and animal studies, with limited human clinical trials to date. While promising anti-inflammatory and antioxidant effects have been demonstrated in cell cultures and experimental models, these results have not yet been replicated in large-scale human studies. More rigorous clinical research is needed to establish safe and effective dosing guidelines for human supplementation.

### Does glycitin interact with common medications or treatments?

Limited research exists on glycitin-drug interactions in humans, though isoflavone compounds generally have mild interactions with certain medications. Individuals taking hormone therapies, anticoagulants, or medications metabolized by CYP3A4 enzymes should consult a healthcare provider before supplementing with glycitin. As with all bioactive compounds, potential interactions may increase at higher doses or with prolonged use.

### Is glycitin safe to take during pregnancy and breastfeeding?

There is insufficient safety data on glycitin supplementation during pregnancy and breastfeeding to establish clear recommendations. Due to its estrogenic potential as an isoflavone and limited human studies in these populations, pregnant and nursing women should avoid glycitin supplements unless specifically directed by their healthcare provider. Consulting with an obstetrician before use is strongly advised.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*